dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Via News Knowledge File

BioNTech SE

organization80% conf.·synced Aug 13, 2026

Biotechnology company involved in patent litigation with Moderna

30
sourced metrics
482
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Clinical Programs
17programs
source
Parameter Count
6asco_2026_presentations
May 22, 2026source
Shareholder Attendance
92percent
May 15, 2026source
Supervisory Board Size
8members
May 15, 2026source
Combination Therapy Trials
5trials
Mar 24, 2026source
Ongoing Clinical Trials
16trials
Mar 24, 2026source
Ongoing Novel Novel Combination Trials
5trials
Mar 24, 2026source
Active Lung Cancer Trials
16trials
Mar 24, 2026source
Phase 3 Trials
4trials
Mar 24, 2026source
Ongoing Phase3 Trials
4trials
Mar 24, 2026source
Company Age
18years
Mar 10, 2026source
Novel Novel Combination Trials
10trials
Jan 12, 2026source
Phase 2 3 Trials Count
25trials
Jan 12, 2026source
Combination Therapy Trials Count
10trials
Jan 12, 2026source
Phase 3 Trials Count
15trials
Jan 12, 2026source
Phase 2 3 Trials
25trials
Jan 12, 2026source
Cash
17.2USD
Dec 31, 2025source
Revenue
2.6-2.8billion_EUR
Nov 30, 2025⚠ sources conflictsource

Stated objectives

2025 R&D expenses target

source
target: EUR 2.0B-EUR 2.2B by 2025-12-31 00:00:00stated

2025 SG&A expenses target

source
target: $550M-$650M by 2025-12-31 00:00:00stated

2025 CapEx for operations target

source
target: $200M-$250M by 2025-12-31 00:00:00stated

Transition to fully integrated commercial oncology company

source
by 2025-12-31 00:00:00stated

Achieve FY 2025 revenue between €2,600M and €2,800M

source
target: 2600-2800 by 2025-12-31 00:00:00stated

Reduce R&D costs to €2,000-2,200M for FY 2025

source
target: 2000-2200 by 2025-12-31 00:00:00stated

Reduce SG&A costs to €550-650M for FY 2025

source
target: 550-650 by 2025-12-31 00:00:00stated

Reduce CapEx to €200-250M for FY 2025

source
target: 200-250 by 2025-12-31 00:00:00stated

File BLA for Trastuzumab Pamirtecan in 2026 pending FDA feedback

source
by 2026-12-31 00:00:00stated

Initiate ROSETTA Breast-01 Phase 3 trial for TNBC by end of 2025

source
by 2025-12-31 00:00:00stated

Relationship graph · 482 connections

Developed by
103
Partnered with
85
Employs
52
Partners with
35
Invested in
34
founded
29
headquartered in
23
Customer of
21
headquartered in
Mainz, Germany
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com